Overriding the G2 checkpoint preferentially sensitizes p53-defected tumor cells to DNA-damaging agents and spares normal cells with wild type p53, which provides a potential therapeutic window for cancer cells with p53 defects, thereby leading to interest in proteins that directly oversee the G2 checkpoint (21, 23, 24). Here, TP53 is linked to cancer.